Bristol Myers Squibb (BMY) Q1 Earnings and Revenues Surpass EstimatesZacks Investment Research • 04/29/22
U.S. Food and Drug Administration Approves Camzyos™ (mavacamten) for the Treatment of Adults With Symptomatic New York Heart Association Class II-III Obstructive Hypertrophic Cardiomyopathy (HCM) to Improve Functional Capacity and SymptomsBusiness Wire • 04/29/22
Octant Raises $80 Million Series B Round to Support Expansion of Next-Generation Drug Discovery Platform, Announces Collaboration with Bristol Myers Squibb and Key AppointmentsBusiness Wire • 04/21/22
Veeva Vault CTMS Launched at Bristol Myers Squibb to Simplify Clinical Trial Processes GloballyPRNewsWire • 04/21/22
EDP Renewables and Bristol Myers Squibb Execute Power Purchase Agreement for the Cattlemen Solar ParkGlobeNewsWire • 04/21/22
Nektar, Bristol Myers Squibb end clinical development of combination therapy including OpdivoMarket Watch • 04/18/22
Nektar and Bristol Myers Squibb Announce Update on Clinical Development Program for Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab)PRNewsWire • 04/14/22